Serious adverse events (including fatalities) have been reported, especially at higher doses. Hypotension and transient apnoea in up to 75% of patients. Arrhythmias, tachycardia.
Bradycardia responsive to atropine has been reported.
Excitatory phenomena such as involuntary movements, twitches, tremors, hypertonus and hiccup in 14% of patients.
Lipaemia and an evolving metabolic acidosis may be precursors of fatal outcomes (propofol infusion syndrome).
During the recovery phase, vomiting, headache and shivering in 2% of patients, with nausea occurring more frequently.
Tissue necrosis following accidental extravascular administration.
| 